कंपनी का अवलोकन
Adagio Medical Holdings, Inc. is a developmental stage medical device company dedicated to the research, development, and commercialization of advanced ablation technologies designed specifically for the treatment of cardiac arrhythmias. This organization operates within the Healthcare sector and functions in the Medical Devices industry, providing specialized therapeutic solutions for conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias. The company's current market capitalization stands at $31.32M, while its annual revenue and total employee count are not publicly disclosed in the available financial data. The valuation indicates that the firm operates as a small-cap entity with a market value that is relatively modest compared to established large-cap peers, reflecting its developmental stage and the high capital requirements typical for medical device innovation.
वित्तीय स्वास्थ्य
The company reported a net income of $-25,084,000 for the trailing twelve months, while EBITDA stood at $-20,920,000, revealing a significant negative gap that highlights substantial operating expenses or non-operating costs eroding profitability before interest and taxes. Free cash flow is reported at $-11,178,500, which indicates that the company is currently burning cash rather than generating liquidity from its operational activities, a common characteristic for developmental stage firms investing heavily in R&D and commercialization efforts. All three key profitability metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, suggesting that either the company has not yet generated significant revenue relative to its costs or is reporting on a basis where traditional margin calculations are not applicable or meaningful at this stage. The balance sheet presents a leveraged structure with total debt of $21.76M against a cash reserve of $17.11M, resulting in a debt-to-equity ratio of 175.44, which signifies a highly leveraged position where liabilities substantially exceed equity. Despite the leverage, the current ratio is 2.44, indicating that the company possesses sufficient current assets to cover its short-term liabilities, thereby maintaining a degree of short-term liquidity despite the negative cash flow. Return on equity is -155.3% and return on assets is -29.8%, metrics that demonstrate the company is currently destroying value for shareholders and utilizing its asset base inefficiently in terms of generating positive returns.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed as -1.33, a negative figure that implies the market is not valuing future earnings based on a traditional multiple but rather focusing on asset backing or potential future cash flows once profitability is achieved. The price-to-book ratio stands at 2.53, indicating that the market values the company at a significant premium of 2.53 times its book value, which may reflect expectations of future asset appreciation or intangible value not captured on the balance sheet. Alternative valuation metrics such as price-to-sales and EV/EBITDA are either unavailable or negative (-1.72 for EV/EBITDA), suggesting that traditional valuation models are less applicable to a firm with negative earnings and limited revenue history. The stock has traded within a range defined by a 52-week high of $2.87 and a 52-week low of $0.73, and without a specific current price, the relative position cannot be calculated, but the wide spread indicates high volatility inherent in small-cap biotech and medical device stocks. The beta value is 0.04, which is exceptionally low and suggests that the stock price has historically exhibited negligible volatility relative to the broader market, a rare characteristic that may indicate limited trading volume or a lack of correlation with general market movements.
Growth & Income
Revenue growth and earnings growth rates for the year-over-year period are not available in the current financial data, preventing a direct comparison of earnings growth relative to revenue expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any generated cash or retained earnings are theoretically available for reinvestment into research and development rather than distribution to shareholders. Since the company is not a dividend payer, it adheres to a growth strategy typical of developmental stage medical device firms, which prioritize capital allocation toward product commercialization over income distribution. The overall growth and income profile is characterized by a complete absence of historical growth metrics and dividend income, relying entirely on potential future product launches and market penetration to drive value creation.